Delving into the Latest Updates on MSD (Japan) Co., Ltd. with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Digestive System Disorders

Neoplasms

Synthetic peptide

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	2
Neoplasms	1

Top 5 Drug Type	Count

Synthetic peptide	1
Small molecule drug	1

Top 5 Target	Count

DPP-4 x SGLT2	1

Since somatosensory evoked potentials (SEP) by hindlimb nerve stimulation are known to ascend bilaterally in the spinal cord, it was investigated whether or not simultaneous bilateral stimulation causes facilitation or inhibition of the stimuli. In an experiment using 36 adult Beagle dogs, the difference between simultaneous bilateral stimulation and unilateral stimulation was studied as to latencies and amplitudes. No significant difference was noted. However, the detection of far-field potentials by bilateral stimulation was not effective in which case far-field potentials did not recorded by unilateral stimulation. It was therefore confirmed that simultaneous bilateral stimulation does not cause facilitation or inhibition in the relay pathways, and does not affect the latency.

Hindustan Antibiotics Bulletin

Evolution of an antibiotic screening program. A tribute to Justo Martinez Mata

Author: Hernandez, Sebastian ; Woodruff, H. Boyd ; Stapley, Edward O.

A review with 70 references is given on 25 yr of an antibiotic screening system and of the many antibiotics identified by this program.

100 Deals associated with MSD (Japan) Co., Ltd.

Login to view more data

100 Translational Medicine associated with MSD (Japan) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

Approved

Other

32

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Sitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline ( DPP-4 x SGLT2 )	Diabetes Mellitus, Type 2 More	Approved
BE-43547A2	Pancreatic Cancer More	Preclinical
BE-22179 ( Top II )	Leukemia More	Discontinued
BE-16627B ( MMPs )	Inflammation More	Discontinued
BQ-518 ( ETA )	Hypertension More	Discontinued